Welcome to the Mendus Q4 2024 report presentation. For the first part of the conference call, the participants will be in listen-only mode. During the Q&A session, participants are able to ask questions by dialing pound key, five on their telephone keypad. Now, I will hand the conference over to the speakers, CEO Erik Manting, and CFO Lotta Ferm. Please go ahead. Thanks, and welcome everybody to the Q4 and year-end webcast and business update of Mendus. My name is Erik Manting, CEO, and I'm together with our CFO, Lotta Ferm. As a summary of the main events of Q4, very importantly, we presented a survival update of our ADVANCE II trial in AML at the American Society of Hematology Conference at the end of last year, which demonstrated continued long-term survival in the majority of patients. We also presented at ASH additional abstracts, which support the broader positioning of vididencel in acute myeloid leukemia and also adjacent diseases such as chronic myeloid leukemia, which may support the further broadening of the addressable patient population with the lead product vididencel. The positive top-line data from the ALISON phase I trial that we presented in December indicate that we have a positive start of treating ovarian cancer patients with vididencel, and that we can observe immune responses after vididencel administration against antigens that have previously been shown to be relevant for ovarian cancer, indicating that we are triggering tumor-directed immune responses. Safety was very good, and we're now awaiting longer-term survival data in Q4 of this year to see how the vididencel product could be potentially developed in ovarian cancer. For the intratumoral primer that we are developing, ilixadencel, we showed that it combines well with the immune checkpoint inhibitor avelumab, and we presented those data at the Society for Immunotherapy of Cancer conference at the end of last year. Unfortunately, the clinical trial that we had anticipated to take place at Institut Bergonié and a number of other larger French hospitals came to an end because the overall trial third-party funding was stopped, and we were part of this trial to study ilixadencel in soft tissue sarcomas, with the trial stopping. That's unfortunately no longer an opportunity, and we will look to potentially partner this program to take it forward in the clinic. Importantly, at the end of last year, we also received feedback from the FDA and the EMA, so the regulatory agencies in the U.S. and Europe, on our registration trial preparations for vididencel, and what that indicated is that we're on the right track. It means we are preparing for a trial that they consider appropriate, but also that the steps we are taking towards that late-stage trial, including the setting up of large-scale manufacturing, are in accordance with their expectations. Finally, the large-scale manufacturing alliance that we have with NorthX Biologics is on track, and that's an important step to take towards pivotal stage readiness. Now, shifting to the numbers of Q4, I'll hand over the word to Lotta. Yeah, hello everyone, and I will not talk so much about this. You can say, but what I would like to highlight is the difference between the costs in the company and the cash burn. As you can see in the report, the costs for the year have been around SEK 136 million, but the cash flow for the year is only SEK 20 million, and that's because of the warrants, which get in some extra cash in the beginning of the year. Also in Q4, the cash positions changed only with SEK 8 million from the end of Q3, and that's because we got some grants and also some interest on the bank accounts. Grants are very important for us because that's how we have funding for most of our preclinical work in the company. The cash runway now will take us until the beginning of 2026. Thanks. As a pipeline overview, we are currently preparing for a registration trial with our lead product vididencel in AML. We are still monitoring the ongoing phase II data from the ADVANCE II trial, and we are expanding the clinical development of vididencel in blood-borne tumors, with the first trial ongoing, which is the CADENCE trial, together with the Australasian Leukaemia and Lymphoma Group. As I indicated, we are also exploring additional indications in the blood-borne tumor space. We have the solid tumor programs, which is the earlier stage ALISON trial in ovarian cancer, which is still to be confirmed in the sense of the next survival readout. We have the ilixadencel program, which we believe would make an interesting partnering opportunity for potential pharmaceutical or other biotechnological companies. Shifting to the main program, the main need for the treatment of AML currently is called maintenance therapy, and the reason is that AML, or acute myeloid leukemia, is a very aggressive blood-borne tumor that affects around 45,000 people annually in Europe and the U.S. only, and around 145,000 people globally. It can only be treated with intensive chemotherapy and immediate chemotherapy to reduce the tumor burden. The big problem is the recurrence of the tumor, and the only way to prevent it currently is a bone marrow or hematopoietic stem cell transplant, but it is unavailable for the majority of patients, and also a lot of patients already relapse before they are even in a position to undergo such a procedure. The need for maintenance therapies that are able to prolong disease-free and overall survival is huge, and that particularly relates to a phenomenon called measurable residual disease, or MRD, which is present in the majority of patients after chemotherapy and is a critical factor in predicting relapse. There is an increased association of relapse with MRD-positive patients. Vididencel addresses this medical need, so it's a maintenance immunotherapy designed to improve relapse-free and overall survival in AML. The way it works is that after the initial treatment, when the disease burden is low, we can administer vididencel through intradermal injections, so injections into the skin. It stimulates the immune system with the aim to reduce the recurrence of the AML. In the ADVANCE II trial, as a reminder, we have administered six vaccinations, four biweekly vaccinations followed by two boosters. The trial was conducted in 10 hospitals across Europe. The active study phase was completed, but we're now in long-term follow-up, and the updated survival data of that long-term follow-up was presented at ASH in December 2024. This was the data we presented, and as you can see, there is a continued long-term survival in the majority of patients, and that's both relapse-free and overall survival of patients that have been treated with vididencel. All of these patients were MRD-positive at study entry, and as you will see, in the first year, a lot of patients relapsed and passed away. It was six patients in this case. The intriguing part is that the majority of patients stayed alive and then also stayed alive over a long period of time. What we could also show and presented at ASH is that the prolonged survival is associated with the immune responses that are stimulated by vididencel treatment. What you see in this graph is the difference between patients that had a sustained immune response, so over time, multiple immune responses following vididencel administration, and they are doing very well and significantly better than the patients without such a sustained vaccine-induced response. We saw more than this. We also saw that B cells play a role, so the cells that produce antibodies, and we also realized that some patients had relatively high levels of suppressor cells called LAG3-positive T cells even before the start of treatment, and that also was predictive of the outcome of the treatment. The treatment itself leads to an increase in B cells and an increase in T cell responses, as you can see in this graph, but also it led to a reduction of these inhibitory T cells. Also at baseline, before we started treating patients, we can already see that the patients that have a poor immune profile are also the patients that relapsed relatively quickly. The other way around, all the patients that had a good immune response were all long-term survivors, and this is a very clear pattern that we can link to the mode of action of vididencel, and combined with the survival data, this is proof of concept that vididencel acts as an active immunotherapy against residual disease in AML, and that puts us in a unique position to move this program forward. We have decided to proceed towards a phase III trial or registration trial and to make sure that the program is ready. On the one hand, that means we are designing the trial and we keep close contact with the regulators to make sure that the trial we design would be a trial that would be sufficient for product registration, but also in parallel, we are setting up the large-scale manufacturing of vididencel. Why is that relevant? It is because you want to have the final production process for your product ready and in place, and also with the material coming out of that process before you start a potential registration trial. You do not want to change the manufacturing protocol during the trial, and that is why this pivotal stage readiness is so much dependent on the manufacturing. With the feedback that we got from EMA and FDA, we got more comfortable with the fact that we are on the right track, and that does not mean only for the trial, but also for the manufacturing and also for the whole dossier that we have around vididencel, the regulatory dossier, but also the way we look at comparability, for example, of the product that we had from our old manufacturing process and now the product that we will get out of the new large-scale manufacturing process. It means that we are on track in preparing for pivotal stage readiness. Why is this important? First and foremost, we want to get this product on the market, right, and that will require, of course, additional means. It can mean a partnership, additional funding, or a combination of both, but one way or the other, the program has to reach this stage because that makes it a product, and I can't emphasize that enough. This pivotal stage readiness is really a crucial milestone in the development of the product, and if we take that hurdle and we are well on the way, I think we have a very attractive program to take forward either by ourselves or in a partnership. The broader AML maintenance landscape looks like this, we are currently treating patients that come out of high-dose or high-intensity chemotherapy, and currently the only approved drug for AML maintenance in that patient population is a drug called oral azacitidine, and this is the current positioning. The trial that we showed, the Advance II trial, is a single-agent trial. It's a monotherapy trial, but as a next step, we want to combine with standard of care. You also have additional maintenance populations in the post-transplant setting, so patients with transplants also have high levels of relapse. Actually, relapse is the most dominant factor for transplant failure, so that is a patient population that could benefit from vididencel treatment. There are also the chemo-unfit patients, patients that are not able to undergo the high-intensity chemotherapy who are today treated by a combination of azacitidine with venetoclax. These are two backbone drugs in the treatment of AML, and when you combine them, we're seeing higher complete remission rates in patients that were previously deemed untreatable or at least not treatable with chemotherapy. That is a big shift in the AML field. It also means that more patients achieve complete remissions with this combination, and they're also eligible for maintenance therapy. The big challenge is that azacitidine, as a backbone drug, is relatively safe but not very effective in the treatment of AML. The other way around, the venetoclax is rather toxic and very effective, but then also very difficult to handle as a maintenance drug, and this is where we believe we have a unique positioning of vididencel in the broader AML landscape. Also, there's additional opportunities in other blood-borne tumors. As step one, we will combine with oral azacitidine. The graph on the right shows the current drug, oral azacitidine, and this was data from the registration trial, so the phase III trial, in MRD-positive patients, and what you will see is that you see a very fast relapse. This is relapse-free survival, and that relapse is slowed down by the azacitidine. That in itself is a reason to combine with azacitidine, but also there is a medical scientific rationale to combine vididencel with oral azacitidine, and the reason is that the azacitidine has been shown in other trials to work very well in combination with immunotherapy approaches, and the main reason being that it increases the immunogenicity of cancer cells. Combined and also based on our own preclinical assessments, we believe that this combination will be beneficial for AML patients. The first trial that we have launched in the expansion of the vididencel clinical development is a trial run by ALLG, the Australasian Leukaemia and Lymphoma Group. The setup of the trial is initially 40 patients to assess safety and tolerability, and then we can expand to a larger trial up to 100 patients extra to look into the feasibility. This trial is for both MRD-positive and MRD-negative patients, and it exposes also the product to a much wider group of hospitals because there's a lot of hospitals associated with ALLG, and we are currently opening up multiple hospitals, or ALLG, I should say, is opening up multiple hospitals throughout Australia to support this trial. We have also looked into the additional maintenance opportunities, and this is just to indicate that we are preparing for additional trials to potentially capture and broaden the addressable patient population in AML and potentially also adjacent diseases such as chronic myeloid leukemia, which is similar in terms of immunological profile, but it's a different kind of disease. It's slower disease than AML, much larger patient population, and there's a high need in chronic myeloid leukemia to provide patients with solutions to don't have to take lifelong drugs, and immunotherapy could bring that solution, but of course we need to test whether vididencel could be a potentially interesting drug to try and achieve those treatment-free remissions. What we have presented at ASH were supportive data for the azacitidine plus venetoclax combination that I mentioned earlier, but also supportive data to study vididencel in chronic myeloid leukemia. If we look at the other programs, the ovarian cancer program, as I mentioned, has shown promising initial data. Not only have we seen tumor-directed responses in the majority of patients, but also most of the patients, 8 out of 12 with vaccine-induced responses, had stable disease at week 22. There seems to be an association between these responses and the disease progression, but we have to be very careful at this point in time to make stronger statements. The next follow-up will be in the fourth quarter of this year when we will have two-year follow-up data from all the patients treated. For ilixadencel, it's a program that we have put a lot of effort in. It's been in the clinic extensively. We've focused on making the manufacturing more robust, and we were ready to go into a trial together with Institut Bergonié, but since the trial that we were part of was stopped, we have to reconsider our strategy, and we have decided to look for potential partners, the main reason being that we have to focus on the lead program where we see the strongest data currently, but also we believe that in solid tumors there will be more and more combination strategies to treat difficult-to-treat tumors, and we want to be part of that, but ideally in the form of a partnership. To summarize, the updated survival data from the ADVANCE II trial at ASH demonstrate and continue to demonstrate durable survival benefit of AML patients treated with vididencel. Preparations for registration trial are ongoing, and they are now also endorsed by the feedback we received end of last year by EMA and FDA. We have established the large-scale manufacturing alliance with NorthX Biologics and are also on track for the major milestone that we want to achieve of GMP readiness, so the readiness to make clinical-grade material in the second half of next year, and that will also be an important milestone for the pivotal stage readiness of vididencel as a program. We are expanding the clinical development of vididencel with the CADENCE trial or AMLM22 CADENCE trial in combination with oral azacitidine, and we are also preparing for additional trial opportunities to broaden the addressable patient population in AML and adjacent diseases. The ilixadencel program is still an opportunity, but we will look to partner that program, and the ALISON phase I trial in ovarian cancer is an earlier stage program which is expected to deliver the next readout based on two-year follow-up in 2025 Q4, after which we can make clearer statements on what we're going to do with that program. With that, I would like to thank you on behalf of the management team and the board and open for Q&A. If you wish to ask a question, please dial pound key, five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key, six on your telephone keypad. The next qu estion comes from Jiaqian Li from Pareto Securities. Please go ahead. Hi, good morning, and thanks for the update. Just two quick questions from me. First one is, you extend the cash runway forecast onto early 2026. Is it based on your current burn rate, and does that include the preparation for the pivotal AML trial? The second question is, could you provide some details on how the CADENCE trial is progressing, and can we still expect the first part of the safety readout in the first half of this year? Thank you. Thanks, Jiaqian. I will let Lotta answer the question on the cash runway, and I will take the question on the CADENCE trial. Yeah, the cash runway is based on the budget we have made for 2025, and that includes all the preparation work for the pivotal stage of vididencel. Yeah, to cut the long story short, the financing we raised in 2023 into early 2024 with the warrants that executed in April was basically meant to take this next milestone, and it means that we try to extend it as long as possible. We, of course, also focus on additional measures, cost-saving measures, but also, for example, grant income to extend the cash runway, but the most important part is that we want to take the milestone of pivotal stage readiness and opening up more opportunities for the program with the cash that we raised in the previous round. Yeah. Yeah. For the CADENCE trial, Jiaqian, to be honest, it's taking longer than we hoped to open up these centers. It's not a lack of interest or a lack of enthusiasm. Particularly, ALLG is very enthusiastic, but when we look into the execution of the trial, it's been slower than we had expected. We had expected to open up already a lot of centers before the year end, and actually they started opening up centers end of last year, and now, of course, they continue to open up more centers, but we are still waiting for the first patient to be treated after that, and that's also been our experience in the ADVANCE II trial, which you typically see is a kind of hockey stick pattern, so that you see a faster ramping up of patient enrollment after the first trials have started enrolling patients, but we're still in that mode as where we are opening up more centers and hopefully get started with the trial. Just to be clear, the trial is not necessary for the progress towards phase III, so the discussions we've been having with EMA and FDA were based on the ADVANCE II data, our plan to move forward in combination with oral azacitidine in an MRD-positive patient population, which is the same patient population that we treated in the ADVANCE II trial. That is all on track. The additional benefit of the CADENCE trial is, first of all, it's good that more people are exposed to the product and that we build up clinical network also in the end to be able to engage in registration trial, and also we have discussed with the regulators that we can use the data from the trial for our global registration dossier, so they'll mainly deliver initially safety data, but we're not dependent on the trial. Okay, thank you. Maybe a follow-up question on this. As you mentioned, the data from CADENCE trial will be fed into the dossier for registration trial, but what if the CADENCE trial is somehow delayed? Will you also start the registration trial later, or you will just start it no matter, regardless of the safety data? Yeah, thanks for that clarifying question, Qian, because we realize that can lead to confusion. The CADENCE trial is really a parallel exercise, so we are not dependent in the phase III preparations on the CADENCE trial. The only thing we have made sure is that data from the trial can be used for the global registration dossier, so not so much the trial, but the dossier of vididencel, and that has to do with the way you collect data. Also, when the trials, for example, run by an external party, in this case ALLG, you have to make sure that you collect data from a trial in a way that you can use them for your product. That is what we have secured, but it's not so that the preparations that we take independently as a company are dependent on any progress or data from the CADENCE trial. Okay, yeah, that's clear. Yeah, thanks for the clarification. Thanks for your questions, Jiaqian. The next question comes from Arron Aatkar from Edison Group. Please go ahead. Hi there, good morning. Thanks very much for taking my questions. First of all, in terms of the cash runway extension into early 2026, you just mentioned now some cost-saving measures to be as efficient as possible. Just wondering if you could provide a bit more color on the sorts of measures taken. It's more that we are looking into processes and routines and so on, and especially in the admin area, to make things more efficient and cheaper and looking over the vendors we are using and so on. It's not that it's going out over the work in the labs or in the clinic and so on. It's just that we try to work a bit smarter where it's possible, and when we have contracts which need to be renegotiated, we try to get something cheaper and so on. Yeah, we are in an incremental processing modus, Arron. That's the long story short, and also we continue to focus on securing grant funding because we do want to keep a healthy balance between the clinical stage programs and the earlier stage research that we do to not only develop new things, but mostly to support actually the progress of the clinical program. So vididencel in blood-borne tumors had the data we presented at ASH, for example, as data that we largely collected ourselves in our own lab, so we want to keep that research engine going, but at the same time, by additional cost-saving measures combined with grant income, we are able to extend and continue to extend our cash runway. Okay, sounds good. Thank you very much. My second question, just looking, it's quite exciting to see vididencel's potential in additional settings, so the combination with azacitidine and venetoclax as well as for chronic myeloid leukemia. You mentioned just earlier about some plans for some phase II trials, so curious to know, will these be pursued alongside the upcoming registration trial, or sort of can you provide any other guidance in terms of timing for these? Yes, first and foremost, the financing that we have raised is focused on reaching phase III readiness, so in the internal communication, now also, of course, external communication about, I call it the highway. The main focus of the company is really about realizing this phase III readiness, but it extends beyond the actual engagement in the phase III trial. I think that will be heavy lifting for which we ideally seek a partner, and otherwise we'll have to raise, of course, substantial funding to engage in it. You need to be ready to do that in any case because the program itself matures by being phase III ready, right? That is by far the biggest effort currently we pursue in the company, and the program has to be ready for phase III, right? Because otherwise you're also not a valuable partner for pharma, for example. That is the part we take care of, and we take care of it with the funding that we secured in the last round. The other trials just indicate that there is a lot of interest to work with the product, and we believe it will be valuable to open up additional opportunities by additional trials, and those can be smaller company-sponsored trials or it can be investigator-sponsored trials, but in principle, we would like to see more addressable patients to be explored with this product, but also, of course, larger groups of clinical centers and clinical hospitals being able to work with the product. That is subject to additional funding, because currently the focus is to get phase III ready and to make sure that we extend our cash runway maximally to make sure that we reach that milestone and then look at all the options available to us. The other trials, however, can become very valuable in the overall course of the development of vididencel, and then it will be a parallel exercise. You focus on the phase III, but then you also have the opportunity to expand your clinical development with additional smaller company-sponsored or investigator-sponsored trials. Excellent. Thank you very much. No more questions from me. Thank you. Thanks, Arron. The next question comes from Christian Binder from Redeye. Please go ahead. Hi, and thanks so much for taking my question. I just have one quick follow-up. You know, you mentioned partnering and you recently attended JPM, etc. Can you just elaborate a little bit on how do you feel the partnering climate is shaping up this year, and do you expect any significant changes that might benefit you? Christian, I think that's the big question, not only for us but also for the whole industry, right? Which is, if you look at what's happening currently, it's a very tough capital market that companies have to navigate through. I think also in terms of partnering, there has been some partnering successfully also, even in the Swedish market, for example, with companies like Calliditas and BioArctic, for example. The opportunities are there, but they are scarce, and there are a lot of companies currently looking for ways forward, and what you start to see now is a kind of new realism that the markets will remain challenging. Pharma partnering will remain a main way forward for a lot of companies, but it's not going to happen for a lot of companies. It's a tough climate. That's the start. I think what is the other mantra in this business is follow the data, right? What you start to see now is a system that was fueled by cheap funding, basically, because of the low interest rates, with a big boom in 2020, going through a significant cooling off, and in the end, the only thing that really creates value is products that deliver meaningful benefit for patients, right? That is a kind of new reality, and I think it's a healthy reality, right? That is where we are in a good position. I think the data that we have, the data that we just summarized today, long-term follow-up in AML combined with the immunomonitoring data, I think that's a pretty strong single-agent activity that we've been able to pick up in a very crowded oncology space, and that stands out. The next step, of course, is can you make that product really ready for late-stage development, including the large-scale manufacturing, keeping everything on track with the regulators, and that is why we are so focused on it. I think that should give us a good position. Of course, I can't go into individual interactions with pharma companies, but what is public information is that a lot of immunotherapy attempts in AML and in blood-borne tumors as a whole have failed. Something is missing. The checkpoint inhibitors, for example, that have revolutionized the treatment of solid tumors have not successfully been applied to blood-borne tumors. We seem to have cracked the code to allow the immune system to take care of residual cells in AML, so I think that is a very strong and unique finding, and if we can translate this into a robust product with large-scale manufacturing and a robust dossier to take things forward to a potential registration trial, I think we're in a good position to talk to anybody, basically. Perfect. That was all from my side. Thanks for the call. Thanks, Christian. As a reminder, if you wish to ask a question, please dial pound key, five on your telephone keypad. The next question comes from Marek Szczeciński ecinski from Private Investor. Please go ahead. Yes, hello. Good morning, and thank you very much for the nice presentation. I have a question regarding the number of patients that we are trying to take in the phase III trial, and the second question, which is follow-up, because the safety from the previous study seems to be very good. Is there any way that the bodies which are granting the permission, like FDA and EMA, they will try to shorten the time for giving the product to the market and rescue more patients? Thank you. Thanks for joining, Marek, and thanks for your question. The long story short is we need to treat a significant amount of patients. Obviously, the effect that we are seeing in the ADVANCE II trial is rather large, so it's not an incremental effect. It's almost a black-and-white effect, right, with patients that respond to the product also have a real long-term survival. If we focus on the MRD-positive patients, they have very high relapse rates, so it should also be possible to have, let's say, a more optimal readout if we focus on the high-risk patients only. With that, we assume we would have to treat roughly 150 patients in a phase III trial, and that would mean we have to open up because it's a relatively rare disease, and there is a lot of competition in the clinical development, particularly of new induction treatments for AML, but you would have to open up roughly 100-120 sites globally. It is going to be quite an extensive trial to get the product registered, and that is the conservative stance we can take now. On the one hand, we can optimize the way we design the trial and limit as much as possible the patient numbers because we think we have an effect large enough to still be able to have an outcome that would be supportive of registration. That is what we have checked, of course, also with EMA and FDA, but at this point, we do not want to be more, let's say, optimistic or aggressive in our statements with respect to potential accelerated approval. There may be ways to do that, but currently, that is not what we are assuming, Marek. Thank you. Thanks. There are no more phone questions at this time, so I hand the conference back to the speakers for any written questions or closing comments. Thanks so much, everybody, for joining. Thanks for the questions, and we look forward to keeping everybody up to date with the progress we anticipate to make in the rest of the year. Have a good day.